GuidelinePediatric blood & cancer2015
SIOP-PODC adapted risk stratification and treatment guidelines: Recommendations for neuroblastoma in low- and middle-income settings.
Guideline in Pediatric blood & cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06928909 (Evaluating the Feasibility of an Intensity-Adapted Pediatric Acute Myeloid Leukemia Treatment Guideline in Malawi), which is not on this map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluating the Feasibility of an Intensity-Adapted Pediatric Acute Myeloid Leukemia Treatment Guideline in Malawi
Who cites it
41 citing papers in PubMed.
- [JMIR research protocols · 2026Article
- Survey of pediatric solid tumor care in economically underdeveloped regions of China.BMC health services research · 2026Article
- Estimates of global causes of death for children and adolescents aged 5-19 in 2000-24: secondary data analysis using bayesian multinomial logistic regression.BMJ (Clinical research ed.) · 2026Article
- Treatment Decision Making at Diagnosis for Children Presenting With Advanced Cancer in Low- and Middle-Income Countries.JCO global oncology · 2026Article
- Outcomes of Childhood Acute Lymphoblastic Leukemia Treated with Modified BFM-2009 Protocol Using Measurable Residual Disease-Based Risk-Stratification: A Single-Center Study.Indian pediatrics · 2026Article
- Survival outcomes and relapse patterns in high-risk metastatic neuroblastoma treated with radiotherapy-only consolidation in a resource-limited setting: a retrospective study from a lower-middle-income country.Frontiers in oncology · 2026Article
- Addressing the drug development challenge for rare pediatric diseases in Japan: a case study of isotretinoin.Investigational new drugs · 2025Review
- Using context-specific evidence to inform resource-stratified cancer guidelines: A call for a new approach.Cancer · 2025Article
- micro-RNA 451-a as a Circulating Biomarker for Neuroblastoma.MicroRNA (Shariqah, United Arab Emirates) · 2025Article
- Therapeutic Innovation in Pediatric Neuroblastoma: Age and Stage-Specific Strategies from Prenatal to Early Childhood-A Review Article.Iranian journal of child neurology · 2025Review
- Prognostic factors of neuroblastoma in limited-resource settings.Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo · 2025Article
- High-risk neuroblastoma in Mexico: from multimodal treatment to immunotherapy. Regarding the first case treated with naxitamab.Frontiers in oncology · 2025Review
- Metronomic chemotherapy in pediatric neuroblastoma.Pediatric discovery · 2024Review
- Exploring treatment decision-making at diagnosis for children with advanced cancer in low- and middle-income countries.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Understanding treatment recommendations at diagnosis of advanced cancer in pediatric oncology: The need to explore decision-making challenges globally.Pediatric blood & cancer · 2024Article
- Dispensing Oral Temozolomide in Children: Precision and Stability of a Novel and Ready to Use Liquid Formulation in Comparison with Capsule Derived Mixtures.Pharmaceutics · 2023Article
- A Multicenter Randomized Bioequivalence Study of a Novel Ready-to-Use Temozolomide Oral Suspension vs. Temozolomide Capsules.Pharmaceutics · 2023Article
- Neuroblastoma Stage 4S (MS): Identification of Risk Factors and Treatment Decisions.Indian journal of pediatrics · 2023Article
- Laparoscopic approach of pediatric adrenal tumors.Pediatric surgery international · 2022Article
- The application and value of radiotherapy at the primary site in patients with high-risk neuroblastoma.The British journal of radiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neuroblastoma is the most common extracranial solid tumor in childhood in high-income countries (HIC), where consistent treatment approaches based on clinical and tumor biological risk stratification have steadily improved outcomes. However, in low- and middle- income countries (LMIC), suboptimal diagnosis, risk stratification, and treatment may occur due to limited resources and unavailable infrastructure. The clinical practice guidelines outlined in this manuscript are based on current published evidence and expert opinions. Standard risk stratification and treatment explicitly adapted to graduated resource settings can improve outcomes for children with neuroblastoma by reducing preventable toxic death and relapse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.